OrganOx Announces Second Private Placement Closing, Investments by Intuitive Ventures and Terumo VenturesOrganOx to benefit from Intuitive Ventures’ and Terumo Ventures’ unique operating and clinical experience
OrganOx Completes $142 Million Equity Financing Led by HealthQuest CapitalFinancing strengthens OrganOx to expand its leadership position in organ technology
OrganOx metra® System Approved for Liver Transplantation in Canada2025 commercial launch planned to expand access to this platform technology
Appointment of Stephen M. Deitsch as new Chief Financial OfficerOXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer (“CFO”) on April 8, 2024. Steve joins OrganOx from Paragon 28 (
NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where he has held the role of CFO since September 2020. Steve’s leadership was instrumental in Paragon 28’s successful IPO on the NYSE in the fall of 2021. Prior to Paragon 28, Steve held CFO roles in a range of public and privately held companies in both the US and Europe.
OrganOx Raises £25 Million in Growth Round Led by Lauxera Capital PartnersOXFORD, United Kingdom, July 17, 2023 (GLOBE NEWSWIRE) -- OrganOx Ltd (“OrganOx” or the “Company”), a world-leading medical technology company committed to making every donated organ count with metra®, a fully automated normothermic machine perfusion (NMP) device for liver transplantation, today announces that it has raised £25 million in a growth round led by Lauxera Capital Partners (“Lauxera”) with support from existing investors.
